This study investigates advanced pancreatic ductal adenocarcinoma. It focuses on the use of investigational, dual-targeting chimeric antigen receptor natural killer (CAR-NK) cells.
The study evaluates the safety, tolerability, and anti-tumor activity of these CAR-NK cell products. It looks at how well these cells can target specific antigens found in tumors.
- Who can participate: Adults aged 18 to 75 with advanced pancreatic ductal adenocarcinoma may participate. Key eligibility factors include confirmed disease progression after standard therapy, specific tumor antigen expression, adequate organ function, and performance status.
- Study details: Participants will receive investigational CAR-NK cell therapy through intravenous infusion. They will undergo regular monitoring and assessments to evaluate the treatment's effects and side effects.
How understandable was the trial content above?
Hard to understand
Easy to understand